| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
2'-Nitroflavonoids (1.25-40 μM; 0-96 h) inhibited the activity of three triple-negative breast cancer (TNBC) cell lines MDA-MB-231, BT-549 and MDA-MB-468, with IC50 values of 4.0 μM, 9.2 μM and 6.5 μM after 72 h of treatment, respectively, and IC50 value of 14.5 μM (96 h) against EA.hy926 endothelial cells [1]. 2'-Nitroflavonoids (0-25 μM; 72-144 h) inhibited the colony formation and migration of triple-negative breast cancer cells and induced cell cycle arrest and apoptosis [1]. 2'-Nitroflavonoids (1-25 μM; 72 h) reduced the protein level of α-tubulin in MDA-MB-231 and BT-549 cells, disrupted the arrangement of α-tubulin in cells, and induced the formation of multipolar mitotic spindles [1].
|
|---|---|
| ln Vivo |
2'-Nitroflavonoids (20 mg/kg; intraperitoneal injection; 5 times a week for 2 weeks) showed antitumor activity in a 4T1 triple-negative breast cancer mouse model [1].
|
| Cell Assay |
Cell cycle analysis [1]
Cell Types: MDA-MB-231 Tested Concentrations: 5 μM Incubation Duration: 72 hours Experimental Results: MDA-MB-231 cells were induced to undergo S phase and G2/M phase arrest. Apoptosis analysis [1] Cell Types: MDA-MB-231 Tested Concentrations: 1, 5, 25 μM Incubation Duration: 72 hours Experimental Results: Compared with the solvent control group, the number of viable cells was significantly reduced and the proportion of early apoptotic cells was significantly increased at the 25 μM concentration. Compared with the solvent control group, the proportion of subdiploid cells was significantly increased at the 5 μM and 25 μM concentrations. Western Blot Analysis [1] Cell Types: MDA-MB-231, BT-549 Tested Concentrations: 1, 5, 25 μM Incubation Duration: 72 hours Experimental Results: At 25 μM, the expression of α-tubulin was significantly reduced in both cell lines. At all test concentrations, the expression level of actin was not affected. |
| Animal Protocol |
Animal/Disease Models:BALB/c (female, 6-8 weeks old, 20-25 g, orthotopic 4T1 cell model) [1]
Doses: 20 mg/kg Route of Administration: Intraperitoneal injection; once daily, 5 times a week for 2 weeks Experimental Results: Compared with the vector control group, the relative tumor volume was significantly reduced. There were significant differences in body weight, liver, spleen, heart or kidney weight among the groups. |
| References |
| Molecular Formula |
C15H9NO4
|
|---|---|
| Molecular Weight |
267.24
|
| CAS # |
53277-26-2
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=C1C2=CC=CC=C2OC(C3=C([N+]([O-])=O)C=CC=C3)=C1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7420 mL | 18.7098 mL | 37.4195 mL | |
| 5 mM | 0.7484 mL | 3.7420 mL | 7.4839 mL | |
| 10 mM | 0.3742 mL | 1.8710 mL | 3.7420 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
